tiprankstipranks
Trending News
More News >
BioCryst Pharmaceuticals (BCRX)
:BCRX

BioCryst (BCRX) AI Stock Analysis

Compare
2,226 Followers

Top Page

BC

BioCryst

(NASDAQ:BCRX)

51Neutral
BioCryst's overall stock score is influenced by strong revenue growth and improvements in cash flow, though it remains challenged by profitability and high leverage. The positive outlook from the earnings call and strategic board appointment provide some optimism, but technical indicators suggest caution due to potential overbought conditions and valuation concerns due to the negative P/E ratio.
Positive Factors
Market Share
Orladeyo market share in HAE will be steady and reliable through competitor product launches.
Pediatric Market Growth
Orladeyo for pediatric patients could provide a nice growth opportunity with about 500 addressable patients in the U.S.
Sales Performance
BioCryst Pharmaceuticals reported a 34.3% year-over-year increase in Orladeyo sales for FY24, showcasing strong performance.
Negative Factors
Biological Risk
Netherton syndrome and kallikrein inhibition in DME are both complicated with slightly more biological risk than normal.
Operational Expenses
The stock experienced a 10% drop, likely due to an overreaction to higher-than-expected 4Q operational expenses.

BioCryst (BCRX) vs. S&P 500 (SPY)

BioCryst Business Overview & Revenue Model

Company DescriptionBioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
How the Company Makes MoneyBioCryst Pharmaceuticals makes money through the sale of its approved drug, Orladeyo, which is used to prevent attacks in patients with hereditary angioedema (HAE). Revenue is primarily generated from product sales and licensing agreements. The company enters into partnerships and collaborations to license its proprietary technology and compounds, providing additional revenue streams through upfront payments, milestone payments, and royalties. Furthermore, BioCryst invests in research and development to expand its pipeline of drug candidates, which may lead to future revenue opportunities upon successful development and commercialization.

BioCryst Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Shows revenue generated from various business segments, providing insight into which divisions are performing well and contributing most to the company's growth.
Chart InsightsBioCryst's Orladeo revenue has shown impressive growth, driven by strong demand and strategic execution, culminating in a 34% year-over-year increase. The company's enhanced guidance for 2025, buoyed by the Inflation Reduction Act, suggests continued momentum. Despite challenges like reauthorization season and foreign exchange impacts, the company's robust pipeline and financial performance position it well for future growth. With plans to expand Orladeo's use and positive cash flow anticipated, BioCryst is poised for a promising trajectory in the coming year.
Data provided by:Main Street Data

BioCryst Financial Statement Overview

Summary
BioCryst shows strong revenue growth and impressive gross margins, but the ongoing unprofitability, negative equity, and high leverage are concerning. Improvements in operating cash flows offer some optimism, yet the firm's financial instability remains a critical issue.
Income Statement
45
Neutral
BioCryst has exhibited significant revenue growth, with a 36% increase from 2023 to 2024, and a notable 110% growth since 2020. The gross profit margin is strong at approximately 97%, indicating effective cost management relative to revenue. However, the company remains unprofitable, with a negative net profit margin of -19.7% in 2024, although this is an improvement from previous years. The negative EBIT and EBITDA margins indicate ongoing operational challenges.
Balance Sheet
30
Negative
The company has a concerning balance sheet with negative stockholders' equity, which suggests potential financial instability. Although the debt-to-equity ratio is not calculable due to negative equity, the high total liabilities relative to assets imply high leverage. The equity ratio of -97% in 2024 highlights this imbalance. These factors indicate potential risks related to solvency and financial flexibility.
Cash Flow
40
Negative
Operating cash flow has improved, reducing from -$95 million in 2023 to -$52 million in 2024. However, free cash flow remains negative, reflecting ongoing cash burn. The free cash flow to net income ratio and operating cash flow to net income ratio are both negative, indicating that cash generation remains a challenge. Despite these issues, the company has managed to grow its free cash flow by 46% year-over-year.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
450.71M331.41M270.83M157.17M17.81M
Gross Profit
438.44M326.75M264.23M149.91M16.14M
EBIT
-2.54M-103.71M-148.44M-177.72M-174.76M
EBITDA
12.81M-116.33M-143.85M-121.74M-167.56M
Net Income Common Stockholders
-88.88M-226.54M-247.12M-184.06M-196.57M
Balance SheetCash, Cash Equivalents and Short-Term Investments
320.85M388.99M442.39M514.43M300.37M
Total Assets
490.42M516.96M550.00M588.15M334.71M
Total Debt
12.82M848.71M741.45M593.24M124.72M
Net Debt
-91.89M714.50M436.69M88.85M-147.41M
Total Liabilities
966.35M972.49M844.60M695.14M353.98M
Stockholders Equity
-475.93M-455.53M-1.45B-1.21B-1.02B
Cash FlowFree Cash Flow
-52.02M-97.31M-163.20M-144.54M-137.73M
Operating Cash Flow
-52.02M-95.14M-161.85M-142.16M-137.22M
Investing Cash Flow
52.59M-131.50M-128.24M15.80M-6.86M
Financing Cash Flow
-5.76M32.48M88.03M359.67M302.70M

BioCryst Technical Analysis

Technical Analysis Sentiment
Positive
Last Price8.93
Price Trends
50DMA
7.79
Positive
100DMA
7.88
Positive
200DMA
7.78
Positive
Market Momentum
MACD
0.33
Negative
RSI
68.71
Neutral
STOCH
89.45
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCRX, the sentiment is Positive. The current price of 8.93 is above the 20-day moving average (MA) of 7.62, above the 50-day MA of 7.79, and above the 200-day MA of 7.78, indicating a bullish trend. The MACD of 0.33 indicates Negative momentum. The RSI at 68.71 is Neutral, neither overbought nor oversold. The STOCH value of 89.45 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BCRX.

BioCryst Risk Analysis

BioCryst disclosed 56 risk factors in its most recent earnings report. BioCryst reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

BioCryst Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
$2.29B-36.38%-40.11%-17.79%
60
Neutral
$1.74B2.6760.26%25.96%
56
Neutral
$1.52B54.64-35.00%43.50%
52
Neutral
$5.35B3.96-42.60%2.86%17.58%1.27%
51
Neutral
$1.87B18.68%36.00%63.50%
45
Neutral
$1.98B-600.68%-98.62%-86.21%
43
Neutral
$1.71B-27.73%-14.19%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BCRX
BioCryst
8.93
3.66
69.45%
ARWR
Arrowhead Pharmaceuticals
14.42
-10.74
-42.69%
MNKD
MannKind
5.00
0.60
13.64%
AGIO
Agios Pharma
30.10
-3.12
-9.39%
IRON
Disc Medicine
49.51
19.34
64.10%
KYMR
Kymera Therapeutics
35.28
-3.02
-7.89%

BioCryst Earnings Call Summary

Earnings Call Date:Feb 24, 2025
(Q4-2024)
|
% Change Since: -3.04%|
Next Earnings Date:May 05, 2025
Earnings Call Sentiment Positive
The earnings call reflects a strong performance for BioCryst, with significant growth in Orladeo revenue, positive financial results, and advancements in the clinical pipeline. However, there are challenges with the reauthorization process and foreign exchange impacts, but they are outweighed by the company's achievements and growth projections.
Q4-2024 Updates
Positive Updates
Record Orladeo Revenue Growth
Orladeo revenue grew by 34% year-over-year. The company added as many patients in 2024 as in the first year of launch, reflecting excellent execution by the commercial team.
Strong Financial Performance
BioCryst generated a non-GAAP operating profit of over $60 million, which is three times larger than planned. Total revenue for 2024 was $450.7 million.
Pipeline Advancements
Progress in clinical trials for BCX1775 in Netherton syndrome and Avoralstat for diabetic macular edema (DME). Plans to file NDA for Orladeo in pediatric use this year.
Positive Impact of Inflation Reduction Act
Higher percentage of Medicare patients on Orladeo can afford co-payments, increasing revenue guidance for Orladeo to $535 million to $550 million for 2025.
Strong Retention and Prescriber Momentum
97% of HAE treaters are considering prescribing Orladeo, with 59% extremely likely to prescribe to more patients. Positive real-world evidence supporting Orladeo's efficacy.
Negative Updates
Challenges in Reauthorization Season
The company is in the middle of the reauthorization season, which could impact revenue for the first quarter, expected to be flat to slightly down versus Q4.
Foreign Exchange Headwinds
There is a reported $5 million headwind in the EU due to foreign exchange fluctuations, affecting revenue.
Uncertainty in Government Funding
There is some increased uncertainty around future government funding for RAPIVAB.
Company Guidance
During BioCryst's fourth quarter 2024 earnings call, the company reported a remarkable year with Orladeo's revenue growing by 34% year-over-year, reaching $437.7 million, and total revenue of $450.7 million. The non-GAAP operating profit exceeded expectations, reaching over $60 million, three times the initial plan. The company increased its Orladeo revenue guidance for 2025 to $535-$550 million, driven by strong demand and the positive impact of the Inflation Reduction Act on Medicare patients' affordability. BioCryst also highlighted progress in its pipeline, with clinical advancements in BCX1775 for Netherton syndrome and Avoralstat for diabetic macular edema. The company is on track to submit a new drug application for Orladeo's pediatric use and anticipates positive cash flow and earnings per share in the second half of 2025.

BioCryst Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
BioCryst Expands Board with New Director Appointment
Positive
May 1, 2025

On April 30, 2025, BioCryst Pharmaceuticals announced the expansion of its Board of Directors from ten to eleven members, with the election of Steven Frank, effective May 2, 2025. Mr. Frank, a respected healthcare investment banker, is expected to bring valuable expertise to the board as BioCryst aims to build on its commercial success and advance its pipeline. The appointment highlights BioCryst’s strategic focus on accelerating towards profitability and enhancing its position in the biopharma industry.

Spark’s Take on BCRX Stock

According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.

BioCryst’s overall stock score reflects strong revenue growth and improvements in cash flow, though it remains challenged by profitability and high leverage. The earnings call provided a positive outlook with robust revenue guidance, highlighting the company’s future potential. However, technical indicators suggest caution, with medium-term weakness and valuation concerns due to the negative P/E ratio.

To see Spark’s full report on BCRX stock, click here.

Executive/Board Changes
BioCryst Appoints CEO as Interim CFO Amid Transition
Neutral
Apr 10, 2025

On February 28, 2025, BioCryst Pharmaceuticals announced the resignation of its Chief Financial Officer and Interim Principal Accounting Officer, Anthony Doyle, effective April 9, 2025. To ensure a smooth transition, Doyle will provide consulting services until May 31, 2025. Subsequently, on April 7, 2025, the company’s Board appointed CEO Jon P. Stonehouse as the Interim CFO and Interim Principal Accounting Officer. The company has also engaged a former biotechnology CFO as a consultant to assist during the transition while searching for a permanent CFO.

Spark’s Take on BCRX Stock

According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.

BioCryst’s stock score reflects strong revenue growth and promising pipeline advancements, tempered by financial instability and technical uncertainty. Positive earnings call developments and corporate announcements provide optimism, yet profitability and solvency remain critical concerns.

To see Spark’s full report on BCRX stock, click here.

Executive/Board Changes
BioCryst CFO Anthony Doyle Resigns Effective April 2025
Neutral
Mar 4, 2025

On February 28, 2025, BioCryst Pharmaceuticals announced the resignation of its Chief Financial Officer, Anthony Doyle, effective April 9, 2025. Doyle, who has been with the company since April 2020, played a crucial role during the global launch of ORLADEYO and in strengthening the company’s financial position as it nears profitability. His departure is not due to any disagreements with the company, and he will remain in his role until April 9 to ensure a smooth transition. The company has initiated a search for a new CFO.

Legal ProceedingsBusiness Operations and StrategyFinancial Disclosures
BioCryst Faces Patent Challenge Amidst Strong Growth
Neutral
Feb 24, 2025

In January 2025, BioCryst received a notice from Annora Pharma, challenging the patents of its drug ORLADEYO, with potential implications for its market exclusivity in the U.S. Despite this, BioCryst reported strong financial results for 2024, with significant revenue growth and an optimistic outlook for 2025. The company is expanding its pipeline with new clinical trials and aims to further increase ORLADEYO’s accessibility and market reach, particularly for pediatric patients with HAE.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.